Delivery Order SPE2DB24D2105-SPE2DB25FAPVE
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) valued at $3,359.77, with an ultimate completion date of September 11, 2025. This competitive award, issued September 10, 2025, utilizes firm fixed-price pricing with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency awarded a delivery order valued at $17,446.83 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) under a firm fixed-price contract with an ultimate completion date of August 19, 2025. This non-set-aside delivery order represents a single procurement action drawn from AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) under a firm fixed-price contract valued at $8,801.10. The order, issued on August 22, 2025, with an ultimate completion date of August 25, 2025, represents a competitively awarded, non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the delivery from its corporate office location. This delivery order...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order by the Defense Logistics Agency's Medical Supply Chain for Multaq 400 mg tablets (60-count units) valued at $4,589.64. The contract, awarded on August 1, 2025, with an ultimate completion date of August 4, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award represents a competitively awarded transaction under...
- The Defense Logistics Agency awarded a $4,632.34 delivery order to AmerisourceBergen Drug Corp for Multaq 400 mg tablets (60-count units) with an ultimate completion date of July 24, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The place of performance is listed as Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $3,059.76 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count packages) under a firm fixed price contract. The order was competitively awarded without set-aside designation and is scheduled for completion by September 10, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this pharmaceutical delivery from its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $25,511.16 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count packages). This is a firm fixed-price, competitively awarded contract with no set-aside designation, with an ultimate completion date of August 13, 2025. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion global pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $13,188.00 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) on September 16, 2025, with an ultimate completion date of September 17, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's Conshohocken, Pennsylvania location. The award represents a single delivery order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency Medical Supply Chain awarded a $57,770.08 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Multaq 400 mg tablets (60-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 4, 2025, with performance based in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at approximately $7K to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units). This competitively awarded, firm fixed-price contract with no set-aside designation was executed on July 28, 2025, with an ultimate completion date of July 29, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- SPE2DB24D2105Indefinite Delivery Contract
- SPE2DB24D2105-SPE2DB25FAPVEDelivery Order
The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for Multaq 400 mg tablets (60-count units) valued at $14,662.54 under a firm fixed-price arrangement. The contract was competitively awarded without set-aside designation and is scheduled for completion by June 26, 2025, one day after the award date. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania served as the place of performance for this pharmaceutical delivery. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies a broad spectrum of medications and medical commodities to support military healthcare programs and the Defense Health Agency. The company's established relationship with DLA and its proven capability to fulfill federal pharmaceutical requirements through open competition made it well-positioned to receive this delivery order for the cardiac medication Multaq, which is used in the treatment of atrial fibrillation.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.7k | 6/25/25 |